- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
ClinicalTrials.gov registry snapshot / 2026-07-24Peptide trials,
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Official registry finder
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
15matching registry records
Snapshot timestampJuly 24, 2026 at 9:00 AM UTC
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusNCT06982859 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 195 estimated | 0 recruiting1 listed / 1 countries | Dec 2026estimated | Jul 16, 2026ClinicalTrials.gov | Open NCT06982859 ↗ |
| A Safety Study of LY3437943 Given as a Single Injection in Healthy ParticipantsNCT03841630 / Eli Lilly and Company | CompletedVerified 2019-08 | Phase 145 actual | 0 recruiting1 listed / 1 countries | Jul 25, 2019actual | Aug 6, 2019ClinicalTrials.gov | Open NCT03841630 ↗ |
| A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)NCT04143802 / Eli Lilly and Company | CompletedVerified 2021-01-15 | Phase 172 actual | 0 recruiting4 listed / 1 countries | Dec 28, 2020actual | Jan 20, 2021ClinicalTrials.gov | Open NCT04143802 ↗ |
| A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)NCT04823208 / Eli Lilly and Company | CompletedVerified 2022-08 | Phase 164 actual | 0 recruiting4 listed / 1 countries | Jun 23, 2022actual | Aug 22, 2022ClinicalTrials.gov | Open NCT04823208 ↗ |
| A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsNCT05445232 / Eli Lilly and Company | CompletedVerified 2023-04-01 | Phase 132 actual | 0 recruiting2 listed / 1 countries | Feb 24, 2023actual | Apr 18, 2023ClinicalTrials.gov | Open NCT05445232 ↗ |
| A Study of LY3437943 in Chinese Participants With Obesity Or OverweightNCT05548231 / Eli Lilly and Company | CompletedVerified 2023-08 | Phase 132 actual | 0 recruiting2 listed / 1 countries | Jul 27, 2023actual | Aug 14, 2023ClinicalTrials.gov | Open NCT05548231 ↗ |
| A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal FunctionNCT05611957 / Eli Lilly and Company | CompletedVerified 2023-09-15 | Phase 129 actual | 0 recruiting4 listed / 1 countries | Sep 5, 2023actual | Oct 2, 2023ClinicalTrials.gov | Open NCT05611957 ↗ |
| A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male ParticipantsNCT05757531 / Eli Lilly and Company | CompletedVerified 2023-07 | Phase 17 actual | 0 recruiting1 listed / 1 countries | Jun 23, 2023actual | Jul 5, 2023ClinicalTrials.gov | Open NCT05757531 ↗ |
| A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionNCT05916560 / Eli Lilly and Company | CompletedVerified 2025-04 | Phase 143 actual | 0 recruiting5 listed / 1 countries | Mar 2, 2025actual | Apr 18, 2025ClinicalTrials.gov | Open NCT05916560 ↗ |
| A Study of LY3437943 in Healthy Participants With a High Body Mass IndexNCT05959096 / Eli Lilly and Company | CompletedVerified 2024-09 | Phase 185 actual | 0 recruiting1 listed / 1 countries | Jul 25, 2024actual | Oct 1, 2024ClinicalTrials.gov | Open NCT05959096 ↗ |
| A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection DevicesNCT06003465 / Eli Lilly and Company | CompletedVerified 2024-03 | Phase 157 actual | 0 recruiting3 listed / 1 countries | Feb 8, 2024actual | Mar 29, 2024ClinicalTrials.gov | Open NCT06003465 ↗ |
| A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseNCT06039826 / Eli Lilly and Company | CompletedVerified 2024-07 | Phase 146 actual | 0 recruiting2 listed / 1 countries | Jul 11, 2024actual | Jul 26, 2024ClinicalTrials.gov | Open NCT06039826 ↗ |
| A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943NCT06313528 / Eli Lilly and Company | CompletedVerified 2025-09 | Phase 185 actual | 0 recruiting3 listed / 1 countries | Aug 26, 2025actual | Sep 23, 2025ClinicalTrials.gov | Open NCT06313528 ↗ |
| To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy ParticipantsNCT06808802 / Eli Lilly and Company | CompletedVerified 2025-06 | Phase 130 actual | 0 recruiting1 listed / 1 countries | Apr 15, 2025actual | Jun 5, 2025ClinicalTrials.gov | Open NCT06808802 ↗ |
| A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaNCT06982846 / Eli Lilly and Company | CompletedVerified 2026-06 | Phase 180 actual | 0 recruiting1 listed / 1 countries | May 4, 2026actual | Jun 18, 2026ClinicalTrials.gov | Open NCT06982846 ↗ |
Recruiting location footprint
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Clinical trial finder FAQ
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
Evidence boundary
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →